LEO Pharma A/S

Leo Pharma has posted a strong set of financials for the first quarter of 2025, “building on build on the momentum that we delivered in 2024,” CEO Christophe Bourdon has told Scrip . Revenues rose by

Leo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova

A decade ago, Almirall took the strategic decision to focus exclusively on medical dermatology, and after posting a strong set of financials for 2024, CEO Carlos Gallardo has told investors that “I’m

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the